

Osteoarthritis - Pipeline Insight, 2021

https://marketpublishers.com/r/OD4D22E310CEEN.html

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: OD4D22E310CEEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Osteoarthritis - Pipeline Insight, 2021," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Osteoarthritis Understanding

Osteoarthritis: Overview

Osteoarthritis (also known as OA) is a common joint disease that most often affects middle-age to elderly people. It is commonly referred to as 'wear and tear' of the joints, but we now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone. Although it is more common in older people, it is not really accurate to say that the joints are just "wearing out." It is characterized by breakdown of the cartilage (the tissue that cushions the ends of the bones between joints), bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining (called the synovium). OA is a top cause of disability in older people. The goal of osteoarthritis treatment is to reduce pain and improve function. There is no cure for the disease, but some treatments attempt to slow disease



progression.

'Osteoarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

Osteoarthritis Emerging Drugs Chapters

This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteoarthritis Emerging Drugs

Ampion: Ampio Pharmaceuticals

Ampion is being developed as an intra-articular injection to treat the signs and symptoms of severe osteoarthritis of the knee (OAK), which continues to be a growing epidemic in the United States and other countries worldwide. Ampion regulates key components of the immune response connected to pain, inflammation, and joint damage in osteoarthritis. In vitro studies show that Ampion reduces the production of the cytokines responsible for inflammation (TNF?, IL-1?, IL-6, IL-12) by regulating with the genetic transcriptional pathways (NF?B, STAT) responsible for the overproduction



of these cytokines while activating anti-inflammatory proteins responsible for tissue growth and healing. This mechanism of action has an overall clinical effect that has been shown to relieve pain and improve function in the knee for patients in clinical trials. Additionally, this mechanism may have the potential to stop, or reverse, disease progression after continued treatment with Ampion, which needs to be evaluated in the clinical. Currently, it is in Phase III stage of clinical trial evaluation to treat osteoarthritis.

Lorecivivint (SM04690): Biosplice Therapeutics

Biosplice Therapeutics has developed an injectable small-molecule inhibitor of the CDC2-like kinase (CLK) and dual-specificity tyrosine regulated kinase (DYRK) family. Biosplice is conducting two large placebo-controlled phase III clinical trials where it hopes to demonstrate reduction in knee osteoarthritis pain with a single injection over the course of 6 months and 12 months, with follow-up beyond a year. Based on the mechanism of action, Biosplice is also exploring the impact lorecivivint plays on inflammation, function, and cartilage protective effects through patient reported outcomes and structural endpoints.

Further product details are provided in the report......

Osteoarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Osteoarthritis

There are approx. 80+ key companies which are developing the therapies for Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Ampio Pharmaceuticals.

Phases

DelveInsight's report covers around 80+ products under different phases of clinical development like







Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.

Osteoarthritis Report Insights

Osteoarthritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Osteoarthritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment



Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Osteoarthritis drugs?

How many Osteoarthritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Osteoarthritis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Ampio Pharmaceuticals

Biosplice Therapeutics

Symic Bio

UnicoCell Biomed CO. LTD



Eupraxia Pharmaceuticals Inc.

Eupravia i Harriadoutidate inc.
Eli Lilly and Company
Xalud Therapeutics, Inc.
ICM Biotech Australia Pty Ltd.
Taiwan Liposomal Company
Gwo Xi Stem Cell Applied Technology Co., Ltd.
K-STEMCELL
Centrexion Therapeutics
Techfields Pharma
AstraZeneca
Merck KGaA
Novartis
Antibe Therapeutics Inc.
Bioventus LLC
PMG Pharm Co., Ltd
Meluha Life Sciences SDN BHD
Anika Therapeutics
MiMedx Group, Inc.
Medivir
Orient Europharma Co., Ltd.



HSRx Biopharmaceutical				
Meiji Seika Pharma				
Peptinov				
Atlanthera				
Yuhan				
OrthoTrophix				
CartilaGen				
Products				
Ampion				
Lorecivivint (SM04690)				
SB-061				
Elixcyte				
V120083				
Tanezumab				
XT-150				
ICM-203				
TLC599				
GXCPC1				

Key

JointStem



CNTX-4975-05
X0002
MEDI7352
M6495
LNA043
ATB-346
PTP-001
PK101
Chondrogen
Cingol
Cingal
Micronized DHACM
_
Micronized DHACM
Micronized DHACM MIV-711
Micronized DHACM MIV-711 2ccPA
Micronized DHACM MIV-711 2ccPA PPV 06
Micronized DHACM MIV-711 2ccPA PPV 06 1102-11
Micronized DHACM MIV-711 2ccPA PPV 06 1102-11 YH 23537



Contents

Introduction

Executive Summary

Osteoarthritis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Ampion: Ampio Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

LNA 043: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

PPV 06: Peptinov

Product Description

Research and Development



Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

CG 001: CartilaGen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Osteoarthritis Key Companies

Osteoarthritis Key Products

Osteoarthritis- Unmet Needs

Osteoarthritis- Market Drivers and Barriers

Osteoarthritis- Future Perspectives and Conclusion

Osteoarthritis Analyst Views

Osteoarthritis Key Companies

Appendix



List Of Tables

LIST OF TABLES

Table 1 Total Products for Osteoarthritis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products



List Of Figures

LIST OF FIGURES

Figure 1	Total	Products	for	Osteoarthriti	S
----------	-------	-----------------	-----	---------------	---

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products



I would like to order

Product name: Osteoarthritis - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/OD4D22E310CEEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/OD4D22E310CEEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970